Critical Comparison: Neurogene (NASDAQ:NGNE) & Rapport Therapeutics (NASDAQ:RAPP)

Rapport Therapeutics (NASDAQ:RAPP) and Neurogene (NASDAQ:NGNE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability and risk.

Insider and Institutional Ownership

52.4% of Neurogene shares are owned by institutional investors. 9.9% of Neurogene shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Rapport Therapeutics and Neurogene”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rapport Therapeutics	N/A	N/A	-$34.79 million	($13.84)	-0.73
Neurogene	$925,000.00	233.18	-$36.32 million	($4.27)	-3.40

Rapport Therapeutics has higher earnings, but lower revenue than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Rapport Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Rapport Therapeutics and Neurogene, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rapport Therapeutics	0	0	3	0	3.00
Neurogene	0	0	7	1	3.13

Rapport Therapeutics currently has a consensus price target of $35.00, indicating a potential upside of 248.26%. Neurogene has a consensus price target of $59.80, indicating a potential upside of 311.85%. Given Neurogene’s stronger consensus rating and higher possible upside, analysts plainly believe Neurogene is more favorable than Rapport Therapeutics.

Profitability

This table compares Rapport Therapeutics and Neurogene’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Rapport Therapeutics	N/A	N/A	N/A
Neurogene	N/A	-32.81%	-27.96%

Summary

Neurogene beats Rapport Therapeutics on 8 of the 12 factors compared between the two stocks.

About Rapport Therapeutics

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

About Neurogene

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.